Renaissance Technologies’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Renaissance Technologies’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-41,100	Closed	-$991K	–	4436
2023 Q1	$991K	Buy	+41,100	New	+$516K	﹤0.01%	2483
2022 Q4	–	Sell	-31,321	Closed	-$141K	–	4527
2022 Q3	$141K	Sell	31,321 -135,426	-81%	-$617K	﹤0.01%	3495
2022 Q2	$667K	Buy	+166,747	New	+$790K	﹤0.01%	2976
2021 Q3	–	Sell	-65,300	Closed	-$550K	–	3971
2021 Q2	$550K	Sell	65,300 -164,100	-72%	-$1.32M	﹤0.01%	2926
2021 Q1	$2.41M	Buy	+229,400	New	+$3.23M	﹤0.01%	2102
2020 Q2	–	Sell	-74,796	Closed	-$688K	–	3864
2020 Q1	$688K	Buy	+74,796	New	+$964K	﹤0.01%	2603
2019 Q3	–	Sell	-15,600	Closed	-$189K	–	3803
2019 Q2	$189K	Buy	+15,600	New	+$84.9K	﹤0.01%	3311

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Renaissance Technologies's PRVB Position: Q2 2023 in Review

Renaissance Technologies sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 41,100 shares — an estimated $991K sold.

Renaissance Technologies first reported a position in PRVB in Q2 2019 and held it in 7 quarters. The position peaked at $2.41M in Q1 2021. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Renaissance Technologies reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Renaissance Technologies sold 41,100 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $991K.
Renaissance Technologies first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 7 quarters.
Renaissance Technologies's Provention Bio, Inc. Common Stock position peaked at $2.41M in Q1 2021.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.